Status:

UNKNOWN

Prospective Pilot Feasibility Study Comparing Envarsus Once-a-day to Tacrolimus Twice-a-day Immunosuppressive Regimen on Drug Bioavailability in Hispanic First Time Kidney Transplant Recipients

Lead Sponsor:

California Institute of Renal Research

Collaborating Sponsors:

Balboa Institute of Transplantation

University of California, San Diego

Conditions:

Kidney Transplant; Complications

Kidney Transplant Failure and Rejection

Eligibility:

All Genders

18+ years

Phase:

PHASE1

Brief Summary

This investigator-initiated post-marketing study will evaluate the role of Hispanic ethnicity on drug dosing of Envarsus in first-time stable renal transplant recipients. Tacrolimus trough drug levels...

Detailed Description

Adequate drug dosing is essential to prevent allograft rejection and subsequent allograft loss. Many studies have shown that serum levels of immunosuppressant medications can be strongly influenced by...

Eligibility Criteria

Inclusion

  • Male or Female 18 years of age or older.
  • The subject is a first time stable renal transplant patients, who have received their transplant at least 3 months before study entry.
  • The subject is willing to commit to the study design.
  • The subject is considered to have stable allograft function defined as no documented rejection episodes within one month of screening.
  • The subject is not currently receiving treatment with other experimental therapies directed at their transplant.

Exclusion

  • The subject has undergone a prior organ or bone marrow transplant.
  • The subject has taken any interacting/contraindicated drug determined by the Investigator within 30 days of administration of the protocol.
  • Any study drug allergies and if there are high serum donor specific antibody levels (DSA) or a high panel reactive antibody level (PRA).
  • Documented treatment of rejection within 30 days of onset of the screening visit.

Key Trial Info

Start Date :

July 11 2018

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

December 1 2023

Estimated Enrollment :

50 Patients enrolled

Trial Details

Trial ID

NCT03438773

Start Date

July 11 2018

End Date

December 1 2023

Last Update

February 9 2023

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

California Institute of Renal Research

San Diego, California, United States, 92123